The DOI matches its Crossref record; 37 of the 40 references it cites were found in a registry or an index, and 3 are not checked yet.
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
Open accessAbstract
BACKGROUND: The most appropriate targets for systolic blood pressure to reduce cardiovascular morbidity and mortality among persons without diabetes remain uncertain. METHODS: We randomly assigned 9361 persons with a systolic blood pressure of 130 mm Hg or higher and an increased cardiovascular risk, but without diabetes, to a systolic blood-pressure target of less than 120 mm Hg (intensive treatment) or a target of less than 140 mm Hg (standard treatment). The primary composite outcome was myocardial infarction, other acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes. RESULTS: At 1 year, the mean systolic blood pressure was 121.4 mm Hg in the intensive-treatment group and 136.2 mm Hg in the standard-treatment group. The intervention was stopped early after a median follow-up of 3.26 years owing to a significantly lower rate of the primary composite outcome in the intensive-treatment group than in the standard-treatment group (1.65% per year vs. 2.19% per year; hazard ratio with intensive treatment, 0.75; 95% confidence interval [CI], 0.64 to 0.89; P<0.001). All-cause mortality was also significantly lower in the intensive-treatment group (hazard ratio, 0.73; 95% CI, 0.60 to 0.90; P=0.003). Rates of serious adverse events of hypotension, syncope, electrolyte abnormalities, and acute kidney injury or failure, but not of injurious falls, were higher in the intensive-treatment group than in the standard-treatment group. CONCLUSIONS: Among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT01206062.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the Systolic Blood Pressure Intervention Trial, 261 patients at high cardiovascular risk who were already using antihypertensive drugs targeting a systolic BP of 120 mmHg had an approximately twofold risk of syncope vs. the control group targeting a systolic BP of 140 mmHg.”
From 2018 ESC Guidelines for the diagnosis and management of syncope (2018) · cites this paper as [261]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results have been interpreted to be generally consistent between the two trials, but ACCORD BP was viewed as underpowered due to the composite primary end point being less sensitive to blood pressure regulation (38,40).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Adverse outcomes, including hypotension, syncope, electrolyte abnormality, and acute kidney injury (AKI), were more common in the intensive treatment arm; risk of adverse outcomes needs to be weighed against the cardiovascular benefit of more intensive blood pressure lowering.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“The primary composite outcome of MI, coronary syndromes, stroke, heart failure, or death from cardiovascular causes was reduced by 25% in the intensive treatment group.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated that treatment to a goal systolic blood pressure of <120 mmHg decreases cardiovascular event rates by 25% in high-risk individuals, although people with diabetes were excluded from this trial (38).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“The results of BPROAD and ESPRIT are supported by the Systolic Blood Pressure Intervention Trial (SPRINT), which demonstrated that treatment to a goal systolic blood pressure of <120 mmHg decreases cardiovascular event rates by 25% in high-risk individuals, although people with diabetes were excluded from this trial (44).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“Adverse outcomes, including hypotension, syncope, electrolyte abnormality, and acute kidney injury (AKI), were more common in the intensive treatment arm”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [44]
In the citing paper
“in which there was a notable 25% relative/0.5% absolute reduced risk per year of cardiovascular morbidity and mortality with intensive (<120 mm Hg) as compared with standard (<140 mm Hg) systolic blood pressure control in patients with hypertension and high cardiovascular risk.71”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [71]
In the citing paper
“This graded approach is based on evidence from multiple meta-analyses and individual RCTs, which show a consistent and graded reduction in CVD risk in response to reductions in TC and LDL-C levels. 61-71”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [70]
In the citing paper
“These trials are consistent in showing that the higher the initial LDL-C level, the greater the absolute reduction in risk, while the relative risk reduction remains constant at any given baseline LDL-C level.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [70]
In the citing paper
“The primary composite outcome of myocardial infarction (MI), coronary syndromes, stroke, heart failure, or death from cardiovascular causes was reduced by 25% in the intensive treatment group.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated that treatment to a target systolic blood pressure of < 120 mmHg decreases cardiovascular event rates by 25% in high-risk patients, although people with diabetes were excluded from this trial (33).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“Of note, the ACCORD BP and SPRINT trials targeted a similar systolic blood pressure < 120 mmHg, but in contrast to SPRINT, the primary composite cardiovascular end point was nonsigni fi cantly reduced in ACCORD BP.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“The achieved systolic blood pressures in the trial were 121 mmHg and 136 mmHg in the intensive versus standard treatment group, respectively.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“Adverse outcomes, including hypotension, syncope, electrolyte abnormality, and acute kidney injury were more common in the intensive treatment arm; risk of adverse outcomes needs to be weighed against the cardiovascular bene fi t of more intensive blood pressure lowering.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“The results have been interpreted to be generally consistent between both trials, but ACCORD BP was viewed as underpowered due to the composite primary end point being less sensitive to blood pressure regulation (33).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Lim, S. S., Vos, T., Flaxman, A. D., Danaei, G., Shibuya, K., Adair-Rohani, H., AlMazroa, M. A., Amann, M., Anderson, H. R., Andrews, K. G., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61766-8 · Cited by 11,805
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447068 · Cited by 11,782
Global burden of hypertension: analysis of worldwide data
Kearney, P. M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P. K., & He, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17741-1 · Cited by 8,698
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Self-citationHeart Disease and Stroke Statistics—2014 Update
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., et al. (2013) · Circulation · doi:10.1161/01.cir.0000441139.02102.80 · Cited by 5,264
Blood pressure, stroke, and coronary heart disease
Collins, R., Peto, R., MacMahon, S., Godwin, J., Qizilbash, N., Collins, R., MacMahon, S., Hebert, P., Eberlein, K. A., Taylor, J. O., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)90944-z · Cited by 4,491
Flagged first, then by citations
Research works printed but not linked: 3
- 10.1016/s0140-6736(05)70151-3 · DOI
- Franklin SS, 1999, Pathol Biol (Paris), 47, 594
- Nwankwo T, 2013, NCHS Data Brief, 133, 1
Cited by
Sorted by citations
Items 301–400 of 1,036
Fatani, N., Dixon, D. L., Van Tassell, B. W., Fanikos, J., & Buckley, L. F. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.01.014 · Cited by 173
Nicolau, J. C., Feitosa, G. S., Petriz, J. L. F., Furtado, R. H. D. M., Précoma, D. B., Lemke, W., Lópes, R. D., Timerman, A., Marin‐Neto, J. A., Bezerra, L., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210180 · Cited by 162
Benefits and Harms of Intensive Blood Pressure Treatment in Adults Aged 60 Years or Older
Weiss, J. W., Freeman, M., Low, A., Fu, R., Kerfoot, A., Paynter, R. A., Motu’apuaka, M. L., Kondo, K. K., & Kansagara, D. L. (2017) · Annals of Internal Medicine · doi:10.7326/m16-1754 · Cited by 173
Beddhu, S., Chertow, G. M., Cheung, A. K., Cushman, W. C., Rahman, M., Greene, T., Wei, G., Campbell, R. C., Conroy, M., Freedman, B. I., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.030848 · Cited by 173
Textile Triboelectric Nanogenerators for Wearable Pulse Wave Monitoring
Chen, G., Au, C., & Chen, J. (2021) · Trends in biotechnology · doi:10.1016/j.tibtech.2020.12.011 · Cited by 173
Hypertension in chronic kidney disease: What lies behind the scene
Ameer, O. Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.949260 · Cited by 173
Band, R. J., Bradbury, K. J., Morton, K., May, C. R., Michie, S., Mair, F. S., Murray, E., McManus, R. J., Little, P. S., & Yardley, L. (2017) · Implementation Science · doi:10.1186/s13012-017-0553-4 · Cited by 172
Sitting Less and Moving More: Implications for Hypertension
Dempsey, P. C., Larsen, R. N., Dunstan, D. W., Owen, N., & Kingwell, B. A. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11190 · Cited by 170
Drawz, P. E., Pajewski, N. M., Bates, J. T., Bello, N. A., Cushman, W. C., Dwyer, J. P., Fine, L. J., Goff, D. C., Haley, W. E., Krousel-Wood, M., et al. (2017) · Hypertension · doi:10.1161/hypertensionaha.116.08076 · Cited by 170
Hypertension and cognitive dysfunction in elderly: blood pressure management for this global burden
Tadić, M., Cuspidi, C., & Hering, D. (2016) · BMC Cardiovascular Disorders · doi:10.1186/s12872-016-0386-0 · Cited by 170
Vascular Cognitive Impairment and Dementia
Wong, E. C., & Chui, H. C. (2022) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001124 · Cited by 170
Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 revision)
Wang, J. (2025) · 老年心脏病学杂志：英文版 · doi:10.26599/1671-5411.2025.01.008 · Cited by 170
Albasri, A., Hattle, M., Koshiaris, C., Dunnigan, A. V., Paxton, B., Fox, S. E., Smith, M. C., Archer, L., Levis, B., Payne, R., et al. (2021) · BMJ · doi:10.1136/bmj.n189 · Cited by 170
Globalization, Work, and Cardiovascular Disease
Schnall, P. L., Dobson, M., & Landsbergis, P. A. (2016) · International Journal of Health Services · doi:10.1177/0020731416664687 · Cited by 168
Gender Differences in Epidemiology, Pathophysiology, and Treatment of Hypertension
Giosia, P. D., Giorgini, P., Stamerra, C. A., Petrarca, M., Ferri, C., & Sahebkar, A. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0716-z · Cited by 168
Kim, H., Lee, E. M., Ahn, S. Y., Kim, K., Kim, H. C., Kim, J. H., Lee, H., Lee, J. H., Park, J., Cho, E. J., et al. (2023) · Clinical Hypertension · doi:10.1186/s40885-023-00234-9 · Cited by 168
Lloyd‐Jones, D. M., Huffman, M. D., Karmali, K. N., Sanghavi, D. M., Wright, J. S., Pelser, C. B., Gulati, M., Masoudi, F. A., & Goff, D. C. (2016) · Circulation · doi:10.1161/cir.0000000000000467 · Cited by 167
Chronic Limb-Threatening Ischemia
Farber, A. M. (2018) · New England Journal of Medicine · doi:10.1056/nejmcp1709326 · Cited by 167
Blood pressure and heart failure
Oh, G. C., & Cho, H. (2020) · Clinical Hypertension · doi:10.1186/s40885-019-0132-x · Cited by 167
Investigation of antihypertensive class, dementia, and cognitive decline
Peters, R. K., Yaşar, S., Anderson, C. S., Andrews, S. J., Antikaínen, R., Arima, H., Beckett, N. S., Beer, J. C., Bertens, A. S., Booth, A., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008732 · Cited by 166
Hypertension—A Public Health Challenge of Global Proportions
Fisher, N. D. L., & Curfman, G. (2018) · JAMA · doi:10.1001/jama.2018.16760 · Cited by 165
Gu, A., Yue, Y., Desai, R. P., & Argulian, E. (2017) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.116.003166 · Cited by 164
Phenotyping of Acute Kidney Injury: Beyond Serum Creatinine
Moledina, D. G., & Parikh, C. R. (2017) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2017.09.002 · Cited by 164
APOL1-Associated Nephropathy: A Key Contributor to Racial Disparities in CKD
Freedman, B. I., Limou, S., Ma, L., & Kopp, J. B. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.06.020 · Cited by 164
Risk Factor Management in Atrial Fibrillation
Brandes, A., Smit, M. D., Nguyen, B. O., Rienstra, M., & Gelder, I. C. V. (2018) · Arrhythmia & Electrophysiology Review · doi:10.15420/aer.2018.18.2 · Cited by 163
INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES"
Dedov, I. I., Shestakova, M. V., Mel'nichenko, G. A., Mazurina, N. V., Andreeva, E. N., Bondarenko, I. Z., Руслановна, Г. З., Dzgoeva, F. K., Елисеев, М. С., Ershova, E. V., et al. (2021) · Obesity and metabolism · doi:10.14341/omet12714 · Cited by 163
Prabhakaran, D., Anand, S., Watkins, D., Gaziano, T., Wu, Y., Mbanya, J. C., Nugent, R., Ajay, V. S., Afshin, A., Adler, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32471-6 · Cited by 162
F. Piepoli, M. (2017) · International Journal of Behavioral Medicine · doi:10.1007/s12529-016-9583-6 · Cited by 162
Wenzel, P., Kossmann, S., Münzel, T. F., & Daiber, A. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.01.027 · Cited by 161
Investigation and Treatment of High Blood Pressure in Young People
Hinton, T., Adams, Z. H., Baker, R. P., Hope, K. A., Paton, J. F. R., Hart, E. C., & Nightingale, A. K. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.13820 · Cited by 161
Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions
Ferguson, L. D., Siebert, S., McInnes, I. B., & Sattar, N. A. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0256-0 · Cited by 160
He, J., Ouyang, N., Guo, X., Sun, G., Li, Z., Mu, J., Wang, D. W., Qiao, L., Xing, L., Ren, G., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02603-4 · Cited by 160
Blood Pressure Trajectories and the Risk of Intracerebral Hemorrhage and Cerebral Infarction
Li, W., Jin, C., Vaidya, A., Wu, Y., Rexrode, K. M., Zheng, X., Gurol, M. E., Ma, C., Wu, S., & Gao, X. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.09479 · Cited by 157
Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy
Han, X., Zhou, Y., & Liu, W. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0034-x · Cited by 156
Strategies for Achieving Healthy Vascular Aging
Nowak, K. L., Rossman, M. J., Chonchol, M., & Seals, D. R. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10439 · Cited by 155
Soliman, E. Z., Ambrosius, W. T., Cushman, W. C., Zhang, Z.-M., Bates, J. T., Neyra, J. A., Carson, T. Y., Tamariz, L. J., Ghazi, L., Cho, M. E., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.028441 · Cited by 155
Ideal Blood Pressure in Patients With Atrial Fibrillation
Kim, D., Yang, P., Kim, T., Jang, E., Shin, H. J., Kim, H. Y., Yu, H. T., Uhm, J., Kim, J., Pak, H., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.05.076 · Cited by 155
Heart failure with preserved ejection fraction: New approaches to diagnosis and management
Upadhya, B., & Kitzman, D. W. (2019) · Clinical Cardiology · doi:10.1002/clc.23321 · Cited by 158
Tsai, W., Wu, H., Peng, Y., Yang, J., Chen, H., Chiu, Y., Hsu, S., Ko, M., Pai, M., Tu, Y., et al. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.0197 · Cited by 154
Clinical trials in older people
Pitkälä, K. H., & Strandberg, T. E. (2022) · Age and Ageing · doi:10.1093/ageing/afab282 · Cited by 154
Wong, N. D., Zhao, Y., Patel, R. J., Patao, C., Malik, S., Bertoni, A. G., Correa, A., Folsom, A. R., Kachroo, S., Mukherjee, J., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2439 · Cited by 153
Impaired Orthostatic Blood Pressure Recovery Is Associated with Unexplained and Injurious Falls
Finucane, C., O’Connell, M. D. L., Donoghue, O. A., Richardson, K., Savva, G. M., & Kenny, R. A. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14563 · Cited by 153
World Heart Federation Roadmap for Hypertension – A 2021 Update
Jeemon, P., Séverin, T., Amodeo, C., Balabanova, D., Campbell, N. R. C., Gaiță, D. I., Kario, K., Khan, T., Melifonwu, R., Moran, A. E., et al. (2021) · Global Heart · doi:10.5334/gh.1066 · Cited by 153
2022 ACC/AHA guideline for the diagnosis and management of aortic disease
Isselbacher, E. M., Preventza, O. A., Black, J. H., Augoustides, J. G., Beck, A. W., Bolen, M. A., Braverman, A. C., Bray, B. E., Brown-Zimmerman, M. M., Chen, E. P., et al. (2023) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2023.04.023 · Cited by 152
Richard, E., Moll van Charante, E. P., Hoevenaar-Blom, M. P., Coley, N., Barbera, M., van der Groep, A., Meiller, Y., Mangialasche, F., Beishuizen, C. B., Jongstra, S., et al. (2019) · The Lancet Digital Health · doi:10.1016/s2589-7500(19)30153-0 · Cited by 150
Filipovský, J., Seidlerová, J., Kratochvíl, Z., Karnosová, P., Hronová, M., & Mayer, O. (2016) · Blood Pressure · doi:10.3109/08037051.2015.1134086 · Cited by 150
Adherence to Antihypertensive Therapy
Peacock, E., & Krousel-Wood, M. A. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.08.005 · Cited by 150
Devuyst, O., Ahn, C., Barten, T. R. M., Brosnahan, G., Cadnapaphornchai, M. A., Chapman, A. B., Gall, É. C.-L., Drenth, J. P. H., Gansevoort, R. T., Harris, P. C., et al. (2025) · Kidney International · doi:10.1016/j.kint.2024.07.009 · Cited by 149
Atrial Fibrillation and Hypertension
Dzeshka, M. S., Shantsila, A., Shantsila, E., & Lip, G. Y. H. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.08934 · Cited by 148
Outcomes of Intensive Blood Pressure Lowering in Older Hypertensive Patients
Bavishi, C., Bangalore, S., & Messerli, F. H. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.10.077 · Cited by 148
Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction
Samson, R., Jaiswal, A., Ennezat, P. V., Cassidy, M. M., & Jemtel, T. H. L. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002477 · Cited by 149
Isolated Systolic Hypertension: An Update After SPRINT
Bavishi, C., Goel, S., & Messerli, F. H. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.08.032 · Cited by 147
Gender differences in hypertension
Reckelhoff, J. F. (2018) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000404 · Cited by 147
2020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation
Барбараш, О. Л., Duplyakov, D. V., Zateischikov, D. A., Панченко, Е. П., Shakhnovich, R. M., Yavelov, I. S., Yakovlev, A. N., Sa, A., Alekyan, B. G., Викторович, А. М., et al. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4449 · Cited by 147
Increasing Participation of Women in Cardiovascular Trials
Cho, L., Vest, A. R., O’Donoghue, M. L., Ogunniyi, M. O., Sarma, A. A., Denby, K. J., Lau, E. S., Poole, J. E., Lindley, K. J., & Mehran, R. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.06.022 · Cited by 149
Unruptured Intracranial Aneurysms
Hackenberg, K. A. M., Hänggi, D., & Etminan, N. (2018) · Stroke · doi:10.1161/strokeaha.118.021030 · Cited by 146
Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.11.027 · Cited by 147
Agarwal, R. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004536 · Cited by 144
Kario, K. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.04.001 · Cited by 144
Reboussin, D. M., Allen, N. B., Griswold, M. E., Güallar, E., Hong, Y., Lackland, D. T., Miller, E. R., Polonsky, T. S., Thompson‐Paul, A. M., & Vupputuri, S. X. (2018) · Circulation · doi:10.1161/cir.0000000000000601 · Cited by 144
T-Cell Mineralocorticoid Receptor Controls Blood Pressure by Regulating Interferon-Gamma
Sun, X.-N., Li, C., Liu, Y., Du, L., Zeng, M., Zheng, X., Zhang, W.-C., Liu, Y., Zhu, M., Kong, D., et al. (2017) · Circulation Research · doi:10.1161/circresaha.116.310480 · Cited by 143
Diuretics for Hypertension: A Review and Update
Roush, G. C., & Sica, D. A. (2016) · American Journal of Hypertension · doi:10.1093/ajh/hpw030 · Cited by 142
The Primary Outcome Is Positive — Is That Good Enough?
Pocock, S., & Stone, G. W. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1601511 · Cited by 142
MacDonald, T. M., Williams, B., Webb, D. J., Morant, S. V., Caulfield, M. J., Cruickshank, J. K., Ford, I., Sever, P., Mackenzie, I. S., Padmanabhan, S., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006986 · Cited by 142
Ding, X., & Zhang, Y. (2019) · Biomedical Engineering Letters · doi:10.1007/s13534-019-00096-x · Cited by 142
Hypertension and Related Cardiovascular Disease Burden in China
Bundy, J. D., & He, J. (2016) · Annals of Global Health · doi:10.1016/j.aogh.2016.02.002 · Cited by 141
Diabetic cardiomyopathy: prevalence, determinants and potential treatments
Gulsin, G. S., Athithan, L., & McCann, G. P. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819834869 · Cited by 141
Hypertension, Obesity, Diabetes, and Heart Failure–Free Survival
Ahmad, F. S., Ning, H., Rich, J. D., Yancy, C. W., Lloyd‐Jones, D. M., & Wilkins, J. T. (2016) · JACC Heart Failure · doi:10.1016/j.jchf.2016.08.001 · Cited by 140
Blood pressure control in type 2 diabetic patients
Grossman, A., & Grossman, E. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0485-3 · Cited by 143
Cerebrovascular Alterations in Alzheimer Disease
Iadecola, C., & Gottesman, R. F. (2018) · Circulation Research · doi:10.1161/circresaha.118.313400 · Cited by 140
Oral Microbiome and Nitric Oxide: the Missing Link in the Management of Blood Pressure
Bryan, N. S., Tribble, G., & Angelov, N. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0725-2 · Cited by 137
Gebremichael, G. B., Berhe, K. K., & Mariye, T. (2019) · BMC Cardiovascular Disorders · doi:10.1186/s12872-019-1091-6 · Cited by 137
The pathogenesis of cerebral small vessel disease and vascular cognitive impairment
Markus, H. S., & Joutel, A. (2025) · Physiological Reviews · doi:10.1152/physrev.00028.2024 · Cited by 140
The latest national clinical guideline for stroke
Rudd, A. G., Bowen, A., Young, G. R., & James, M. A. (2017) · Clinical Medicine · doi:10.7861/clinmedicine.17-2-154 · Cited by 136
Potok, O., Ix, J. H., Shlipak, M. G., Katz, R., Hawfield, A. T., Rocco, M. V., Ambrosius, W. T., Cho, M. E., Pajewski, N. M., Rastogi, A., et al. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.05.017 · Cited by 136
Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients
van Dorst, D. C. H., Dobbin, S. J. H., Neves, K. B., Herrmann, J., Herrmann, S. M., Versmissen, J., Mathijssen, R. H. J., Danser, A. H. J., & Lang, N. N. (2021) · Circulation Research · doi:10.1161/circresaha.121.318051 · Cited by 136
Cognitive Impairment and Dementia After Stroke: Design and Rationale for the DISCOVERY Study
Rost, N. S., Meschia, J. F., Gottesman, R. F., Wruck, L. M., Helmer, K. G., Greenberg, S. M., on behalf of the DISCOVERY Investigators*, Barrett, K. M., Biffi, A., Boden-Albala, B. M., et al. (2021) · Stroke · doi:10.1161/strokeaha.120.031611 · Cited by 136
Redefining Blood-Pressure Targets — SPRINT Starts the Marathon
Perkovic, V., & Rodgers, A. (2015) · New England Journal of Medicine · doi:10.1056/nejme1513301 · Cited by 136
Rocco, M. V., Sink, K. M., Lovato, L., Wolfgram, D. F., Wiegmann, T. B., Wall, B. M., Umanath, K., Rahbari-Oskoui, F. F., Porter, A. C., Pisoni, R., et al. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.08.021 · Cited by 135
Cardiopulmonary Impact of Particulate Air Pollution in High-Risk Populations
Newman, J. D., Bhatt, D. L., Rajagopalan, S., Balmes, J. R., Brauer, M. D., Breysse, P. N., Brown, A. G. M., Carnethon, M. R., Cascio, W. E., Collman, G. W., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.10.020 · Cited by 135
Kaneko, H., Yano, Y., Itoh, H., Morita, K., Kiriyama, H., Kamon, T., Fujiu, K., Michihata, N., Jo, T., Takeda, N., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.052624 · Cited by 134
Fleg, J. L., Evans, G. W., Margolis, K. L., Barzilay, J. I., Basile, J., Bigger, J. T., Cutler, J. A., Grimm, R. H., Pedley, C. F., PETERSON, K. A., et al. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07474 · Cited by 133
Bromfield, S. G., Ngameni, C.-A., Colantonio, L. D., Bowling, C. B., Shimbo, D., Reynolds, K., Safford, M. M., Banach, M., Toth, P. P., & Muntner, P. (2017) · Hypertension · doi:10.1161/hypertensionaha.116.09390 · Cited by 133
Clinical Pharmacology of Antihypertensive Therapy for the Treatment of Hypertension in CKD
Sinha, A. D., & Agarwal, R. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04330418 · Cited by 133
Malhotra, R., Craven, T., Ambrosius, W. T., Killeen, A. A., Haley, W. E., Cheung, A. K., Chonchol, M., Sarnak, M., Parikh, C. R., Shlipak, M. G., et al. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.07.015 · Cited by 132
The LifeLines Cohort Study: Prevalence and treatment of cardiovascular disease and risk factors
van der Ende, M. Y., Hartman, M. H. T., Hagemeijer, Y. P., Meems, L. M. G., de Vries, H. S., Stolk, R. P., de Boer, R. A., Sijtsma, A., van der Meer, P., Rienstra, M., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.061 · Cited by 132
Chow, C. K., Thakkar, J. B., Bennett, A., Hillis, G. S., Burke, M., Usherwood, T. P., Vo, K., Rogers, K. D., Atkins, E., Webster, R. J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30260-x · Cited by 132
Rosenzweig, J. L., Bakris, G. L., Berglund, L., Hivert, M., Horton, E. S., Kalyani, R. R., Murad, M. H., & Vergès, B. L. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-01338 · Cited by 133
Weldegiorgis, M., & Woodward, M. (2020) · BMC Nephrology · doi:10.1186/s12882-020-02151-7 · Cited by 132
Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape
Mende, C. W. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01994-2 · Cited by 134
Kario, K., Chen, C.-H., Park, S., Park, C. G., Hoshide, S., Cheng, H., Huang, Q., & Wang, J.-G. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10238 · Cited by 131
White coat syndrome and its variations: differences and clinical impact
Pioli, M. R., Ritter, A. M. V., de Faria, A. P., & Modolo, R. (2018) · Integrated Blood Pressure Control · doi:10.2147/ibpc.s152761 · Cited by 130
Canadian Cardiovascular Society 2022 Guidelines for Peripheral Arterial Disease
Abramson, B. L., Al-Omran, M. A., Anand, S. S., Albalawi, Z., Coutinho, T. A., de Mestral, C., Dubois, L. A., Gill, H. L., Greco, E., Guzman, R., et al. (2022) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2022.02.029 · Cited by 133
Bhailis, A. M. D., & Kalra, P. A. (2022) · British Journal of Hospital Medicine · doi:10.12968/hmed.2021.0440 · Cited by 130
Coronary Atherosclerosis: Pathophysiologic Basis for Diagnosis and Management
Boudoulas, K. D., Triposkiadis, F. K., Geleris, P., & Boudoulas, H. K. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.04.003 · Cited by 129
Juraschek, S. P., Daya, N. R., Rawlings, A. M., Appel, L. J., Miller, E. R., Windham, B. G., Griswold, M. E., HEISS, G. M., & Selvin, E. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.2937 · Cited by 129
Sustainability of Blood Pressure Reduction in Black Barbershops
Victor, R. G., Blyler, C. A., Li, N., Lynch, K., Moy, N. B., Rashid, M. A., Chang, L. C., Handler, J., Brettler, J. W., Rader, F., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.038165 · Cited by 129
White, W. B., Wakefield, D. B., Moscufo, N., Guttmann, C. R. G., Kaplan, R. F., Bohannon, R. W., Fellows, D., Hall, C. B., & WOLFSON, L. I. (2019) · Circulation · doi:10.1161/circulationaha.119.041603 · Cited by 129
2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Kim, N. H., Seo, J. A., Kim, M. K., Lim, J. H., et al. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0282 · Cited by 130
Beddhu, S., Greene, T., Boucher, R., Cushman, W. C., Wei, G., Stoddard, G., Ix, J. H., Chonchol, M., Kramer, H., Cheung, A. K., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30099-8 · Cited by 128
Metadata
- Authors
- The SPRINT Research Group
- Affiliations
- University Hospitals Cleveland Medical Center (US)
- Corresponding author
- The SPRINT Research Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-26
- Volume
- 373
- Issue
- 22
- Pages
- 2103-2116
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4689591
- OpenAlex
- W3150595609
- Cited by
- 6,325
- References
- 38
- Citations by year
- 2026: 390 · 2025: 449 · 2024: 437 · 2023: 498 · 2022: 523 · 2021: 602 · 2020: 570 · 2019: 694 · 2018: 734 · 2017: 767 · 2016: 613 · 2015: 40
- FWCI
- 522.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000093, UL1TR000050, UL1TR001427, UL1TR000073, UL1TR001064, UL1TR001085, UL1TR000002, UL1TR000075, UL1TR000064, UL1TR000005, UL1TR000433, UL1TR000003, UL1TR000445, UL1TR000439, UL1TR000105)
- National Institute on Aging (P30AG021332)
- National Heart, Lung, and Blood Institute (HHSN268200900040C, A-HL-13-002-001, HHSN268200900049C, HHSN268200900048C, HHSN268200900047C, HHSN268200900046C)
- National Institute of General Medical Sciences (P30GM103337)
- National Center for Research Resources (UL1RR025755, UL1RR024134, UL1RR025752, UL1RR025771)
- National Center for Advancing Translational Sciences (9U54TR000017‐06)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Keywords
- intensive blood pressure control, systolic blood pressure target, antihypertensive therapy, cardiovascular risk, cardiovascular events, all-cause mortality, adverse events, hypotension, acute kidney injury, non-diabetic patients
- MeSH terms
- Age Factors, Aged, Antihypertensive Agents, Blood Pressure, Cardiovascular Diseases, Cause of Death, Female, Goals, Humans, Hypertension, Male, Middle Aged, Risk Factors, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
